Provided by Tiger Fintech (Singapore) Pte. Ltd.

X4 Pharmaceuticals Inc

4.30
+0.600016.22%
Post-market: 4.300.00000.00%19:45 EDT
Volume:265.23K
Turnover:1.12M
Market Cap:24.89M
PE:1.99
High:4.35
Open:3.83
Low:3.83
Close:3.70
Loading ...

X4 Pharmaceuticals Price Target Maintained With a $3.00/Share by Cantor Fitzgerald

Dow Jones
·
26 Mar

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ...

GuruFocus.com
·
26 Mar

X4 Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Mar

X4 Pharmaceuticals: Q4 Earnings Snapshot

Associated Press Finance
·
25 Mar

X4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For €28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Announced In February 2025, The Company Believes It Has Sufficient Funds To Support Operations Into 1H Of 2026

Benzinga
·
25 Mar

X4 Pharmaceuticals Q4 2024 GAAP EPS $(0.20) Misses $(0.17) Estimate, Sales $1.43M Beat $1.04M Estimate

Benzinga
·
25 Mar

BRIEF-X4 Pharmaceuticals Q4 Net Income USD -39.821 Million

Reuters
·
25 Mar

X4 Pharmaceuticals Q4 Net Income USD -39.821 Million

THOMSON REUTERS
·
25 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

X4 Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
21 Mar

X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries

MT Newswires Live
·
19 Feb

BRIEF-X4 Pharmaceuticals And Taiba Rare Announce Exclusive Agreement For The Distribution And Commercialization Of Xolremdi® (Mavorixafor) In Whim Syndrome In Select Middle East Countries

Reuters
·
19 Feb

X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of Xolremdi® (Mavorixafor) in Whim Syndrome in Select Middle East Countries

THOMSON REUTERS
·
19 Feb

X4 Pharmaceuticals Price Target Maintained With a $1.50/Share by HC Wainwright & Co.

Dow Jones
·
07 Feb

X4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall

MT Newswires Live
·
06 Feb

X4 Pharmaceuticals announces strategic restructuring, reduces headcount by 30%

TIPRANKS
·
06 Feb

X4 Pharmaceuticals Inc - to Reduce Headcount by 43 People, Close Vienna Facility

THOMSON REUTERS
·
06 Feb

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

THOMSON REUTERS
·
06 Feb

X4 Pharmaceuticals Inc - Restructuring Expected to Extend Cash Runway Into H1 2026

THOMSON REUTERS
·
06 Feb

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

GlobeNewswire
·
06 Feb